Literature DB >> 27921044

Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome.

Christoph Grander1, Felix Grabherr1, Alexander R Moschen1, Herbert Tilg1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease throughout the world. Pathophysiological insights into this disease have recently illustrated that various factors such as insulin resistance, innate immunity, metabolic inflammation, and the microbiota are of relevance. NAFLD, metabolic syndrome (MS), and type 2 diabetes (T2D) share many pathophysiological aspects, and inflammatory processes in the adipose tissue, gut, and liver have evolved to be of exceptional importance. Most of NAFLD patients are obese and encounter a high risk of developing MS and T2D. NAFLD, however, is also highly common in subjects with MS and T2D. Furthermore, reflecting its nature of a multisystem disease, NAFLD is associated with a high prevalence and incidence of cardiovascular and chronic kidney disease. These facts require screening strategies for MS/T2D in NAFLD patients and vice versa. Thus, the question of cause or effect cannot be answered as MS and NAFLD share many pathomechanisms, and at the time of either diagnosis both frequently coexist. This is also reflected by a global prevalence rate of 25% for both NAFLD and MS. For this reason, it is crucial that physicians are aware of the 'unholy liaison' between MS, T2D, and NAFLD.

Entities:  

Keywords:  Adiponectin; Cytokines; Inflammation; Insulin resistance; Treatment

Year:  2016        PMID: 27921044      PMCID: PMC5122994          DOI: 10.1159/000448940

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  58 in total

1.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

Review 2.  Extrahepatic complications of nonalcoholic fatty liver disease.

Authors:  Matthew J Armstrong; Leon A Adams; Ali Canbay; Wing-Kin Syn
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

Review 3.  From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.

Authors:  Alexander Wree; Lori Broderick; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-20       Impact factor: 46.802

4.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.

Authors:  Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass
Journal:  Hepatology       Date:  2012-07-26       Impact factor: 17.425

5.  IKK-beta links inflammation to obesity-induced insulin resistance.

Authors:  Melek C Arkan; Andrea L Hevener; Florian R Greten; Shin Maeda; Zhi-Wei Li; Jeffrey M Long; Anthony Wynshaw-Boris; Giuseppe Poli; Jerrold Olefsky; Michael Karin
Journal:  Nat Med       Date:  2005-01-30       Impact factor: 53.440

6.  Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.

Authors:  Stefan Kiechl; Jürgen Wittmann; Andrea Giaccari; Michael Knoflach; Peter Willeit; Aline Bozec; Alexander R Moschen; Giovanna Muscogiuri; Gian Pio Sorice; Trayana Kireva; Monika Summerer; Stefan Wirtz; Julia Luther; Dirk Mielenz; Ulrike Billmeier; Georg Egger; Agnes Mayr; Friedrich Oberhollenzer; Florian Kronenberg; Michael Orthofer; Josef M Penninger; James B Meigs; Enzo Bonora; Herbert Tilg; Johann Willeit; Georg Schett
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

7.  Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes.

Authors:  Anna M Wolf; Dominik Wolf; Holger Rumpold; Barbara Enrich; Herbert Tilg
Journal:  Biochem Biophys Res Commun       Date:  2004-10-15       Impact factor: 3.575

8.  Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.

Authors:  Wolfram Goessling; Joseph M Massaro; Ramachandran S Vasan; Ralph B D'Agostino; R Curtis Ellison; Caroline S Fox
Journal:  Gastroenterology       Date:  2008-09-20       Impact factor: 22.682

9.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.

Authors:  Raluca Pais; Fréderic Charlotte; Larissa Fedchuk; Pierre Bedossa; Pascal Lebray; Thierry Poynard; Vlad Ratziu
Journal:  J Hepatol       Date:  2013-05-09       Impact factor: 25.083

10.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.

Authors:  Norikazu Maeda; Iichiro Shimomura; Ken Kishida; Hitoshi Nishizawa; Morihiro Matsuda; Hiroyuki Nagaretani; Naoki Furuyama; Hidehiko Kondo; Masahiko Takahashi; Yukio Arita; Ryutaro Komuro; Noriyuki Ouchi; Shinji Kihara; Yoshihiro Tochino; Keiichi Okutomi; Masato Horie; Satoshi Takeda; Toshifumi Aoyama; Tohru Funahashi; Yuji Matsuzawa
Journal:  Nat Med       Date:  2002-06-17       Impact factor: 53.440

View more
  9 in total

1.  Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study.

Authors:  Jie Xing; Xue Guan; Qian Zhang; Shuohua Chen; Shouling Wu; Xiujing Sun
Journal:  Obes Facts       Date:  2021-03-29       Impact factor: 3.942

2.  Molecular changes in hepatic metabolism in ZDSD rats-A new polygenic rodent model of obesity, metabolic syndrome, and diabetes.

Authors:  Lu Han; Stefanie Bittner; Dachuan Dong; Yuan Cortez; Alex Bittner; Jackie Chan; Meenakshi Umar; Wen-Jun Shen; Richard G Peterson; Fredric B Kraemer; Salman Azhar
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-24       Impact factor: 5.187

3.  Ginsenoside Rg1 Regulates Liver Lipid Factor Metabolism in NAFLD Model Rats.

Authors:  Yunhe Hou; Danshan Gu; Jianzhi Peng; Kerong Jiang; Zhigang Li; Jing Shi; Shikun Yang; Shude Li; Xiaoming Fan
Journal:  ACS Omega       Date:  2020-05-05

Review 4.  CEACAM1 in Liver Injury, Metabolic and Immune Regulation.

Authors:  Andrea Kristina Horst; Sonia M Najjar; Christoph Wagener; Gisa Tiegs
Journal:  Int J Mol Sci       Date:  2018-10-11       Impact factor: 5.923

5.  The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients.

Authors:  Yue-Yan Hu; Ning-Ling Dong; Qiu Qu; Xu-Fan Zhao; Hong-Ju Yang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

Review 6.  Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus.

Authors:  Lung-Wen Tsai; Yi-Hsiang Lu; Rajni Dubey; Jeng-Fong Chiou
Journal:  J Diabetes Res       Date:  2021-11-11       Impact factor: 4.011

7.  Liver fat content is independently associated with microalbuminuria in a normotensive, euglycaemic Chinese population: a community-based, cross-sectional study.

Authors:  Xiaoming Li; Mingfeng Xia; Hui Ma; Yu Hu; Hongmei Yan; Wanyuan He; Huandong Lin; Nai Qing Zhao; Jian Gao; Xin Gao
Journal:  BMJ Open       Date:  2021-06-29       Impact factor: 2.692

8.  IMM-H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high-fat diet.

Authors:  Huijie Shi; Qingchun Wang; Liu Yang; Shouxia Xie; Haibo Zhu
Journal:  FEBS Open Bio       Date:  2017-08-29       Impact factor: 2.693

9.  The association of hepatic steatosis and fibrosis with heart failure and mortality.

Authors:  Jiyun Park; Gyuri Kim; Hasung Kim; Jungkuk Lee; You-Bin Lee; Sang-Man Jin; Kyu Yeon Hur; Jae Hyeon Kim
Journal:  Cardiovasc Diabetol       Date:  2021-09-28       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.